Showing results (691-700 of 735) with videos related to

Sort By:
Pageof 74
European Journal of Cancer (Oxford, England : 1990)|June 15, 2019
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanomaAlexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
The New England Journal of Medicine|September 30, 2014
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanomaGeorgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
The New England Journal of Medicine|September 12, 2017
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV MelanomaJeffrey Weber, Mario Mandala, Michele Del Vecchio, et al.
European Journal of Cancer (Oxford, England : 1990)|February 27, 2022
Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanomaOliver J Kennedy, Michal Kicinski, Sara Valpione, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2023
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238James Larkin, Michele Del Vecchio, Mario Mandalá, et al.
Nature|February 19, 2025
Clonal driver neoantigen loss under EGFR TKI and immune selection pressuresMaise Al Bakir, James L Reading, Samuel Gamble, et al.
Science (New York, N.Y.)|November 7, 2020
Preexisting and de novo humoral immunity to SARS-CoV-2 in humansKevin W Ng, Nikhil Faulkner, Georgina H Cornish, et al.
Cancer Discovery|December 29, 2020
Metastasis and Immune Evasion from Extracellular cGAMP HydrolysisJun Li, Mercedes A Duran, Ninjit Dhanota, et al.
Nature Medicine|April 12, 2023
Body composition and lung cancer-associated cachexia in TRACERxOthman Al-Sawaf, Jakob Weiss, Marcin Skrzypski, et al.
Pageof 74